Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusion
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Analgesia
Conditions
Analgesia
Trial Timeline
Jul 2, 2018 → Oct 26, 2018
NCT ID
NCT04102267About Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusion
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusion is a approved stage product being developed by Heron Therapeutics for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT04102267. Target conditions include Analgesia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04102267 | Approved | Completed |
Competing Products
20 competing products in Analgesia